BioHarvest Sciences to begin human clinical study with multiple sclerosis-related optic neuritis скачать в хорошем качестве

BioHarvest Sciences to begin human clinical study with multiple sclerosis-related optic neuritis

BioHarvest Sciences CEO Ilan Sobel joined Proactive's Steve Darling to share news the company has agreed to a collaboration with the International Neurorehabilitation Institute in Maryland to perform a clinical trial to assess the capacity of the company’s red grape cell (RGC) composition to promote eye health. RGC is produced using BioHarvest's Botanical-Synthesis technology. Sobel told Proactive the study will be an open-label clinical study to evaluate the impact of RGC on multiple sclerosis-related optic neuritis driven by inflammation. The Multiple Sclerosis Foundation estimates more than 1 million people in the US and about 2.5 million people worldwide have been diagnosed with MS. #proactivinvestors #cse #bhsc #otcqb #cnvcf #pharma #biotech #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews